Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

AIM: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is known to be associated with type 2 diabetes mellitus (T2DM) in high rate. The improvement in hepatic function due to sodium-glucose co-transporter 2 (SGLT2) inhibitors has been reported in T2DM patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Metab Syndr Obes
Main Authors: Seko, Yuya, Nishikawa, Taichiro, Umemura, Atsushi, Yamaguchi, Kanji, Moriguchi, Michihisa, Yasui, Kohichiroh, Kimura, Mayumi, Iijima, Hiroaki, Hashimoto, Toshio, Sumida, Yoshio, Okanoue, Takeshi, Itoh, Yoshito
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6267487/
https://ncbi.nlm.nih.gov/pubmed/30568471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S184767
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados